Chongqing Genrix Biopharmaceutical Co.,Ltd. (688443.SH) announced that the company has recently received a Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial application for the company's investigational product GR2303 injection has been approved, permitting the initiation of clinical trials for inflammatory bowel disease indication. As of the announcement date, no drugs targeting the same target as GR2303 injection have been approved for marketing in China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments